A Systematic Overview of Chemotherapy Effects in Gastric Cancer

References

• Cancer Incidence in Sweden 1999. The Swedish Cancer Registry. The National Board of Health and Welfare, Stock-holm. (01)
   Google Scholar
• Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric car-cinoma. Cancer 1991; 67 (Suppl. 1): 260–5. (L2)
   Google Scholar
• Bleiberg H, Gerard B, Deguiral P. Adjuvant therapy in resectable gastric cancer. Br J Cancer 1992; 66: 987-91. (L1)
   PubMedGoogle Scholar
• Crookes P, Leichman CG, Leichman L, et al. Systemic chemotherapy for gastric carcinoma followed by postopera-tive intraperitoneal therapy: a final report. Cancer 1997; 79: 1767-75. (P2/59)
   Google Scholar
• Frasci G, Iaffaioli RV, Comella G, et al. Intraperitoneal adjuvant immuno-chemotherapy in operable gastric cancer with serosal involvement. Clin Oncol R Coll Radiol 1994; 6: 364-70. (P3/91)
   Google Scholar
• Macdonald JS, Fleming TR, Peterson RF, et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) vs surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 1995; 2: 488-94. (C1/193)
   Google Scholar
• Ajani JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preop-erative therapy. World J Surg 1995; 19: 216-20. (L1)
   Google Scholar
• Findlay M, Cunningham D. Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 1993; 19: 29-44. (L1)
   Google Scholar
• The Gastrointestinal Tumor Study Group (GITSG). Con-trolled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group. Cancer 1982; 49: 1116-22. (C2/142)
   Google Scholar
• Geoffroy F, Grem JL. Chemotherapy of advanced gas-trointestinal cancer. Curr Opin Oncol 1994; 6: 427-34. (L2)
   Google Scholar
• Wils J. The treatment of advanced gastric cancer. Semin Oncol 1996; 23: 397-406. (L1)
   Google Scholar
• TNM classification of malignant tumors. UICC P Hermanek, LH Sobin, Editors, 4th edition Springer, Berlin Heidelberg New York 1987. (01)
   Google Scholar
• TNM Classification of Malignant Tumours (4th ed., 2nd rev.). UICC: P Hermanek, LH Sobin, editors. Springer Verlag, Berlin 1992. (01)
   Google Scholar
• Japanese classification of gastric cancer. Japanese Research Society for Gastric Cancer Kanehara Publishers. Tokyo, 1995. (01)
   Google Scholar
• Fukushima M. Adjuvant therapy of gastric cancer: the Japanese experience. Semin Oncol 1996; 23: 369-78. (L2)
   Google Scholar
• Baker LH, Talley RW, Matter R, et al. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. Cancer 1976; 38: 1–7. (C3/39)
   Google Scholar
• MacDonald JS, Schein PS, Woolley PV, et al. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemother-apy for advanced gastric cancer. Ann Intern Med 1980; 93: 533-6. (P3/62)
   Google Scholar
• Wils JA. Perspectives in chemotherapy of advanced gastric cancer. Anti Cancer Drugs 1991; 2: 133-7. (L1)
   Google Scholar
• Douglass HO Jr. Adjuvant therapy of gastric cancer: Have we made any progress? Ann Oncol 1994; 5 (Suppl. 3): 49–57. (02)
   Google Scholar
• Lise M, Nitti D, Marchet A, et al. Adjuvant treatment for gastric cancer. Anticancer Drugs 1991; 2: 433-45. (L1)
   Google Scholar
• Macdonald JS, Schnall SF. Adjuvant treatment of gastric cancer. World J Surg 1995; 19: 221-5. (L2)
   Google Scholar
• Nakajima T. Review of adjuvant chemotherapy for gastric cancer. World J Surg 1995; 19: 570-4. (L2)
   Google Scholar
• Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; H: 1441–7. (M1)
   Google Scholar
• Alcobendas F, Milla A, Estape J, et al. Mitomycin C as an adjuvant in resected gastric cancer. Ann Surg 1983; 198: 13-7. (C3/70)
   Google Scholar
• Allum WH, Hallissey MT, Kelly KA. Adjuvant chemotherapy in operable gastric cancer-5 year follow-up of the first British Stomach Cancer Group Trial. Lancet 1989; 1: 157–74. (C2/ 411)
   Google Scholar
• Estape J, Grau JJ, Alcobendas F, et al. Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg 1991; 213: 219–21. (C2/70)
   Google Scholar
• Fielding JW, Fagg SL, Jones BG, et al. An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British Stomach Cancer Group. World J Surg 1983; 7: 390-9. (C3/441)
   Google Scholar
• Grau JJ, Estapé J, Alcobendas F, et al. Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer 1993; 29A: 340-2. (C3/134)
   Google Scholar
• Hallissey MT, Dunn JA, Ward LC, et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994; 343: 1309-12. (C1/283)
   Google Scholar
• Schlag P, Schreml W, Gaus W, et al. Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: 3-year results. Recent Results Cancer Res 1982; 80: 277-83. (C2/98)
   Google Scholar
• Schlag P. Adjuvant chemotherapy in gastric cancer. World J Surg 1987; 11: 473-7. (C3/103)
   Google Scholar
• Serlin O, Wolkoff J, Amadeo JM, et al. Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to the surgical managemant of carcinoma of the stomach. Cancer 1969; 24: 223-8. (C2/239)
   Google Scholar
• Nakajima T, Fukami A, Ohashi I, et al. Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharma-col Biopharm 1978; 16: 209-16. (C3/430)
   Google Scholar
• Huguier M, Destroyes JP, Baschet C, et al. Gastric carcinoma treated by chemotherapy after resection. Am J Surg 1980; 139: 197-9. (C3/53)
   Google Scholar
• Nakajima T, Fukami A, Tagaki K, et al. Adjuvant chemother-apy with mitomycin C and with a multi-drug combination of mitomycin-C, 5-fluorouracil and cytosine arabinoside after curative resection of gastric cancer. Jpn J Clin Oncol 1980; 10: 187-94. (C2/120)
   Google Scholar
• The Gastrointestinal Tumor study Group (GITSG). A com-parative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma. Cancer 1982; 49: 1362-6. (C1/205)
   Google Scholar
• Higgins GA, Amadeo JH, Smith DE, et al. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. Cancer 1983; 52: 1105-12. (C1/134)
   Google Scholar
• Nakajima T, Takahashi T, Takagi K, et al. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 1984; 2: 1366-71. (C1/223)
   Google Scholar
• Engstrom PF, Lavin PT, Douglass HO Jr, et al. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer 1985; 55: 1868–73. (C1/180)
   Google Scholar
• The Italian Gastrointestinal Tumor Study Group. Adjuvant treatments following curative resection for gastric cancer. Br J Surg 1988; 75: 1100-4. (C1/213)
   Google Scholar
• Coombes RC, Schein PS, Chilvers CE, et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin and mito-mycin with no treatment in operable gastric cancer. J Clin Oncol 1990; 8: 1362-9. (C1/281)
   Google Scholar
• Krook JE, O'Connell MJ, Wieand HS, et al. A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991; 67: 2454-8. (C2/125)
   Google Scholar
• Chou FF, Sheen-Chen SM, Liu PP, et al. Adjuvant chemother-apy for resectable gastric cancer: a preliminary report. J Surg Oncol 1994; 57: 239-42. (C3/115)
   Google Scholar
• Lise M, Nitti D, Marchet A, et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in re-sectable gastric cancer. J Clin Oncol 1995; 13: 2757-63. (C1/314)
   Google Scholar
• Lerner A, Gonin R, Steele GD Jr, et al. Etoposide, doxoru-bicin, and cisplatin chemotherapy for advanced gastric adeno-carcinoma: results of a phase II trial. J Clin Oncol 1992; 10: 536-40. (P3/36)
   Google Scholar
• Neri B, de Leonardis V, Romano S, et al. Adjuvant chemother-apy after gastric resection in node-positive cancer patients: a multicentre randomised study. Br J Cancer 1996; 73: 549-52. (C2/103)
   Google Scholar
• Tsavaris N, Tentas K, Kosmidis P, et al. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy 1996; 42: 220-6. (C3/84)
   Google Scholar
• Jakesz R, Dittrich C, Funovics J, et al. The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial. Recent Results Cancer Res 1988; 110: 44-51. (C2/102)
   Google Scholar
• Sasako M, Sano T, Katai H, et al. Overview of clinical trials on adjuvant chemotherapy for curatively resected gastric cancer. Gan To Kagaku Ryoho 1994; 21 (Suppl. 3): 384–94. (L2)
   Google Scholar
• Ward LC, Fielding JW, Dunn JA, et al. The selection of cases for randomised trials: a registry survey of concurrent trial and non-trial patients. The British Stomach Cancer Group. Br J Cancer 1992; 66: 943-50. (01)
   PubMedGoogle Scholar
• Coombes RC, Chilvers CE, Amadori D, et al. Randomised trial of epirubicin vs fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study. Ann Oncol 1994; 5: 33-6. (C2/69)
   Google Scholar
• Fisher B, Gunduz N, Coyle J. Presence of a growth stimulation factor in serum following primary tumor removal in mice. Cancer Res 1989; 49: 1996-2001. (01)
   Google Scholar
• Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979; 39: 3861-5. (01)
   Google Scholar
• Fink U, Stein HJ, Schuhmacher C, et al. Neoadjuvant chemotherapy forgastric cancer. update. World J Surg 1995; 19: 509-16. (L2)
   Google Scholar
• Bonatsos C, Aust J, Meisner D, et al. Preoperative chemother-apy for patients with locally advanced gastric carcinoma. Proc Am Soc Clin Oncol 1985; 4 Abstr 83. (P3/5)
   Google Scholar
• Philip PA, Austin GJ, Ledermann JA, et al. Weekly etoposide, methotrexate and actinomycin D, alternating with cyclophos-phamide plus vincristine (EMA/C0): a phase II study in advanced gastric carcinoma. Clin Oncol R Coll Radiol 1991; 3: 214-6. (P3/27)
   Google Scholar
• Wilke H, Preusser P, Fink U, et al. Preoperative chemotherapy in locally advanced and non-resectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7: 1318-26. (P2/34)
   Google Scholar
• Wils J, Bleiberg H, Dalesio O, et al. An EORTC gastrointes-tinal group evaluation of the combination of sequential methotrexate (MTX) and 5-fluorouracil (F), combined with adriamycin (A) (FAMTX) in advanced measurable gastric cancer. J Clin Oncol 1986; 4: 1799-803. (P1/71)
   Google Scholar
• Wils J, Meyer HJ, Wilke H. Current status and future directions in the treatment of localized gastric cancer. Ann Oncol. 1994; 5 (Suppl. 3): 69–72. (L2)
   Google Scholar
• Averbach AM, Jacquet P. Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br J Surg 1996; 83: 726-33. (L1)
   Google Scholar
• Rougier P, Lasser P, Ducreux M, et al. Preoperative chemotherapy of locally advanced gastric cancer. Ann Oncol 1994; 5 (Suppl. 3): 59–68. (L2)
   Google Scholar
• Wilke H, Stahl M, Fink U, et al. Preoperative chemotherapy for unresectable gastric cancer. World Surg 1995; 19: 210-5. (L2)
   Google Scholar
• Ajani JA, Ota DM, Jessup M, et al. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer 1991; 68: 1501-6. (P2/25)
   Google Scholar
• Wilke H, Preusser P, Fink U, et al. High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer-a phase 11 study in elderly patients or patients with cardiac risk. Invest New Drugs 1990; 8: 65-70. (P2/34)
   Google Scholar
• Wilke H, Preusser P, Fink U, et al. New developments in the treatment of gastric carcinoma. Semin Oncol 1990; 17 (Suppl. 2): 61–70. (P2/145, P2/36, P3/51)
   Google Scholar
• Plukker JT, Mulder NH, Sleijer DTH, et al. Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: Phase II study with methotrexate and 5-fluorouracil. Br J Surg 1991; 78: 955-8. (P3/20)
   Google Scholar
• Leichman L, Silberman H, Leichman CG, et al. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol 1992; 10: 1933-42. (P2/38)
   Google Scholar
• Yonemura Y, Sawa T, Kinoshita K, et al. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993; 17: 256-61. (C3/55)
   Google Scholar
• Ajani JA, Mayer RJ, Ota DM, et al. Preoperative and postoperative combination chemotherapy for potentially re-sectable gastric carcinoma. J Natl Cancer Inst 1993; 85: 1839-44. (P2/48)
   Google Scholar
• Rougier P, Mahjoubi M, Lasser P, et al. Neoadjuvant chemotherapy in locally advanced gastric carcinoma-a phase 11 trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer 1994; 30A: 1269-75. (P3/30)
   Google Scholar
• Ajani JA, Roth JA, Putnam JB, et al. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. Eur J Cancer 1995; 31A: 665-70. (P2/32)
   Google Scholar
• Fink U, Schuhmacher C, Stein HJ, et al. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg 1995; 82: 1248-52. (P2/30)
   Google Scholar
• Plukker JT, Sleijfer DT, Verschueren RC, et al. Neo-adjuvant chemotherapy with carboplatin, 4-epiadriamycin and teniposide (CET) in locally advanced cancer of the cardia and the lower oesophagus: a phase II study. Anticancer Res 1995; 15: 2357-61. (P3/19)
   Google Scholar
• Kelsen D, Karpeh M, Schwartz G, et al. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cis-platin plus intravenous fluorouracil. J Clin Oncol 1996; 14: 1818-28. (P2/60)
   Google Scholar
• Melcher AA, Mort D, Maughan TS. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Br J Cancer 1996; 74: 1651–4. (P2/27)
   Google Scholar
• Songun I, Keizer HJ, Hermans J, et al. Chemotherapy for operable gastrric cancer: results of the Dutch randomised FAMTX trial. Eur J Cancer 1999; 35: 558-62. (C3/59)
   Google Scholar
• Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorou-racil (ECF). Ann Oncol 1994; 5: 609-16. (P1/139)
   Google Scholar
• Gunderson LL, Sosin H. Adenocarcinoma of the stomach: Areas of failure in a reoperation series (second or symptomatic looks): clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982; 8: 1-11. (01)
   PubMedGoogle Scholar
• Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987; 11: 418-25. (01)
   Google Scholar
• Wisbeck W, Becker E, Russell A, et al. Adenocarcinoma of the stomach: Autopsy observations with therapeutical impli-cations for the radiation oncologist. Radiother Oncol 1986; 7: 13-8. (01)
   PubMedGoogle Scholar
• Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1-11. (02)
   Google Scholar
• Kaibara N, Iitsuka Y, Kimura A, et al. Relationship between area of serosal invasion and prognosis in patients with gastric carcinoma. Cancer 1987; 60: 136-9. (02)
   Google Scholar
• Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinet-ics and growth of metastases. Cancer Res 1983; 43: 1488-92. (01)
   Google Scholar
• Dixon WJ, Longrnire WP Jr, Holden WD. Use of ri-ethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric and colorectal carcinoma: ten year follow-up. Ann Surg 1971; 173: 26-39. (C2/277)
   Google Scholar
• Adachi W, Koike S, Rafique M, et al. Preoperative intraperi-toneal chemotherapy for gastric cancer, with special reference to delayed peritoneal complications. Surg Today 1995; 25: 396-403. (P2/23)
   Google Scholar
• Hamazoe R, Maeta M, Kaibara N. Intraperitoneal ther-mochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 1994; 73: 2048-52. (C2/82)
   Google Scholar
• Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peri-toneal recurrence of gastric cancer: randomized controlled study. World J Surg 1994; 18: 150-5. (C3/58)
   Google Scholar
• Yonemura Y, Ninomiya I, Kaji M, et al. Prophylaxis with intraoperative chemohyperthermia against peritoneal recur-rence of serosal invasion-positive gastric cancer. World J Surg 1995; 19: 450-4. (P2/160)
   Google Scholar
• Ikeguchi M, Kondou A, Oka A, et al. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg 1995; 161: 581-6. (R3/174)
   Google Scholar
• Yonemura Y, Fujimura T, Nishimura G, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996; 119: 437-44. (P2/83)
   Google Scholar
• Kaibara N, Hamazoe R, Iitsuka Y, et al. Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer. Hepatogastroenterology 1989; 36: 75-8. (C2/82)
   Google Scholar
• Takahashi T, Hagiwara A, Shimotsuma M. Intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles for patients with advanced gastric cancer. Eur J Surg Oncol 1994; 20: 183-4. (L3)
   Google Scholar
• Schiessel R, Funovics J, Schick G, et al. Adjuvant intraperi-toneal cisplatin therapy in patients with operated gastric carcinoma: Results of a randomized trial. Acta Med Austriaca 1989; 16: 68-9. (C2/64)
   Google Scholar
• Atiq OT, Kelsen DP, Shiu MH, et al. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorou-racil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J Clin Oncol 1993; 11: 425-33. (P2/35)
   Google Scholar
• Tsujitani S, Watanabe A, Abe Y, et al. Intraperitoneal administration of cisplatin and etoposide during surgery for patients with gastric cancer. Anticancer Res 1993; 13: 2497-9. (P3/13)
   Google Scholar
• Jones AL, Trott P, Cunningham D, et al. A pilot study of intraperitoneal cisplatin in the management of gastric cancer. Ann Oncol 1994; 5: 123-6. (P3/18)
   Google Scholar
• Takahashi T, Hagiwara A, Shimotsuma M, et al. Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. World J Surg 1995; 19: 565-9. (C2/113)
   Google Scholar
• Yu W, Whang I, Suh I, et al. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adju-vant to resectable gastric cancer. Ann Surg 1998; 228: 347-54. (C1/248)
   Google Scholar
• Sautner T, Hofbauer F, Depisch D, et al. Adjuvant intraperi-toneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994; 12: 970-4. (C2/67)
   Google Scholar
• Bamias A, Hill ME, Cunningham D, et al. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. Cancer 1996; 77: 1978-85. (P1/235)
   Google Scholar
• Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-8. (C2/61)
   Google Scholar
• Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil vs fluorou-racil, doxorubicin, and methotrexate in advanced esopha-gogastric cancer. J Clin Oncol 1997; 15: 261-7. (C1/274)
   Google Scholar
• Lopez M, Perno CF, Di Lauro L, et al. 5-fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer. Cancer Chemother Pharmacol 1984; 12: 194-7. (P3/32)
   Google Scholar
• Wils JA, Klein HO, Wagener DJT, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-a step ahead in the treatment of advance gastric cancer: a trial the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827-31. (C1/208)
   Google Scholar
• Preusser P, Wilke H, Achterrath W, et al. Phase II study with the combination etoposide, doxorubicin and cislatin in ad-vanced measurable gastric cancer. J Clin Oncol 1989; 7: 13 10–7. (P2/69)
   Google Scholar
• Arbuck SG, Silk Y, Douglass HO Jr, et al. A phase II trial of 5-fluorouracil, doxorubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. Cancer 1990; 65: 2442-5. (P3/32)
   Google Scholar
• Figoli F, Galligioni E, Crivellari D, et al. Evaluation of two consecutive regimens in advanced gastric cancer. Cancer Invest 1991; 9: 257-62. (P3/71)
   Google Scholar
• Anderson H, Scarffe JH, Ransom M, et al. MMAF for advanced gastric cancer. Eur J Cancer 1991; 27: 1234-338. (P2/65)
   Google Scholar
• Feliu J, Giron CG, Gonzalez-Baron M, et al. Alternating chemotherapy in advanced gastric cancer. A phase II study. Cancer Chemother Pharmacol 1991; 28: 313-4. (P3/22)
   Google Scholar
• Lacave AJ, Baron FJ, Anton LM, et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 1991; 2: 751-4. (P2/56)
   Google Scholar
• Raschko JW, Johnson EA, Ueno W, et al. Continuous infusion 5-fluorouracil with bolus adriamycin and mitomycin and low-dose cisplatin (FAMP) in the treatment of metastatic gastric carcinoma: an evaluation of efficacy and toxicity. Cancer Invest 1991; 9: 49-51. (P3/12)
   Google Scholar
• Wilke H, Preusser P, Fink U, et al. New developments in the treatment of gastric carcinoma. Cancer Treat Res 1991; 55: 363–73. (P2/145, P2/35, P3/51)
   PubMedGoogle Scholar
• Zaniboni A, Simoncini E, Marpicati P, et al. Mitomycin-C, adriamycin, 5-fluorouracil and leucovorin (L-FAM2) in the treatment of advanced gastric cancer: a phase II study. Tumori 1991; 77: 160-3. (P3/30)
   Google Scholar
• Pazdur R, Ajani JA, Winn R, et al. A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previ-ously untreated metastatic gastric carcinoma. Cancer 1992; 69: 878-82. (P3/44)
   Google Scholar
• Jeremic B, Acimovic LJ, Matovic M. Carboplatin and etoposide in patients with advanced gastric cancer. J Chemother 1993; 5: 266-70. (P3/36)
   Google Scholar
• Koizumi W, Kurihara M, Sasai T, et al. A phase II study of combination therapy with 5'-deoxy- 5-fluorouridine and cis-platin in the treatment of advanced gastric cancer with primary foci. Cancer 1993; 72: 658-62. (P3/51)
   Google Scholar
• Cervantes A, Villar-Grimalt A, Abad A, et al. 5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer, A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Ann Oncol 1993; 4: 753-7. (P2/90)
   Google Scholar
• Kornek G, Schulz F, Depisch D, et al. A phase I-II study of epirubicin, 5-fluorouracil, and leucovorin in advanced adeno-carcinoma of the stomach. Cancer 1993; 71: 2177-80. (P3/37)
   Google Scholar
• Gebbia V, Testa A, Valenza R, et al. Combination chemother-apy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/ or metastatic adenocarcinoma of the stomach. J Chemother 1994; 6: 147-51. (P3/37)
   Google Scholar
• Gebbia V, Valenza R, Testa A, et al. Etoposide, doxorubicin (Adriamycin) and cisplatin regimen in advanced gastric ade-nocarcinoma: experience with a lower dose schedule. J Cancer Res Clin Oncol 1994; 120: 550-2. (P3/21)
   Google Scholar
• Hayakawa M, Morise K, Chin K, et al. Combination chemotherapy with Tegafur.Uracil (UFT), etoposide, adri-amycin and cisplatinum (UFT-EAP) for advanced gastric cancer. Jpn J Clin Oncol 1994; 24: 282–8. (P3/34)
   Google Scholar
• Rougier P, Ducreux M, Mahjoubi M, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994; 30A: 1263-369. (P2/87)
   Google Scholar
• Scarpellini M, Tononi A, Pasquini E, et al. Etoposide, doxorubicin and cisplatin (EAP regimen) in advanced gastric cancer. J Chemother 1994; 6: 211-5. (P3/24)
   Google Scholar
• Highley MS, Parnis FX, Trotter GA, et al. Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocar-cinoma. Br J Surg 1994; 81: 1763-5. (P2/34)
   Google Scholar
• Berenberg JL, Tangen C, Macdonald JS, et al. Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study. Cancer 1995; 76: 715-9. (P1/ 76)
   Google Scholar
• Clark JL, Kucuk O, Neuberg DS, et al. Phase II trial of etoposide, doxorubicin, and cisplatin combination in ad-vanced measurable gastric cancer. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1995; 18: 318-24. (P3/31)
   Google Scholar
• di Bartolomeo M, Bajetta E, de Braud F, et al. Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. Oncology 1995; 52: 41-4. (P3/42)
   Google Scholar
• Gonzalez-Baron M, Feliu J, Espinosa E, et al. Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group. Cancer Chemother Phar-macol 1995; 36: 255–8. (P3/46)
   Google Scholar
• Van Cutsem E, Filez L, Dewyspelaere J, et al. Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: a phase II study. Anticancer Res 1995; 15: 1079-80. (P3/30)
   Google Scholar
• Zaniboni A, Barni S, Labianca R, et al. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cancer 1995; 76: 1694-9. (P2/53)
   Google Scholar
• Ychou M, Astre C, Rouanet P, et al. A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer. Eur J Cancer 1996; 32A: 1933-7. (P3/28)
   Google Scholar
• Cascinu S, Labianca R, Graziano F, et al. Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 65-leucovorin, glu-tathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. Br J Cancer 1998; 78: 390-3. (P1/105)
   Google Scholar
• Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41. (C3/40)
   Google Scholar
• Scheithauer W, Kornek G, Zeh B, et al. Palliative chemotherapy vs supportive care in patientes with metastatic gastric cancer: A randomized trial. Second International Conference on Biology, Prevention and Treatment of GI Malignancy, Köln, Germany 1995, p 68. (C3/37)
   Google Scholar
• Pyrhönen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrex-ate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587–91. (C2/41)
   Google Scholar
• Moertel CG, Mittelman JA, Bakemeier RF. Sequential and combination chemotherapy of advanced gastric cancer. Can-cer 1976; 38: 678-82. (C3/146)
   Google Scholar
• Douglass HO Jr, Lavin PT, Goudsmit A, et al. An eastern cooperative oncology group evaluation of combinations of methyl-CCNU, mitomycin, Adriamycin and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 1984; 2: 1372-81. (C2/183)
   Google Scholar
• The Gastrointestinal Tumor Study Group (GITSG). Ran-domized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group. Cancer 1984; 53: 13-7. (C1/232)
   Google Scholar
• Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985; 253: 2061-7. (C2/151)
   Google Scholar
• Levi JA, Fox RM, Tattersall MH, et al. Analysis of a prospectively randomized comparison of doxorubicin vs 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J Clin Oncol 1986; 4: 1348-55. (C1/187)
   Google Scholar
• The Gastrointestinal Tumor Study Group (GITSG). Triazi-nate and platinyum efficacy in combination with 5-fluorou-racil and doxorubicin: results of at three-arm randomized trial in metastatic gastric cancer. J Natl Cancer Inst 1988; 80: 1011–5. (C1/247)
   Google Scholar
• Kurihara M, Izumi T, Yoshida S, et al. A cooperative randomized study on tegafur plus mitomycin C vs combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. Jpn J Cancer Res 1991; 82: 613-20. (C3/169)
   Google Scholar
• Diaz-Rubio E, Jimeno J, Aranda E, et al. Etoposide (E) epirubicin (E)cisplatin (P) combination chemotherapy(EEP) in advanced gastric cancer: negative impact on clinical outcome. Spanish Cooperative Group for GI Tumor Ther-apy (T.T.D.). Ann Oncol 1992; 3: 861–3. (C1/109)
   Google Scholar
• Kelsen D, Atiq OT, Saltz L, et al. FAMTX vs etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10: 541-8. (C2/60)
   Google Scholar
• Kyoto Research Group for Chemotherapy of Gastric Can-cer. A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) vs 5-fluorouracil, cisplatin, and 4'-epiru-bicin (FPEPIR). Kyoto Research Group for Chemotherapy of Gastric Cancer (KRGCGC), Anticancer Res 1992; 12: 1983-8. (C2/60)
   Google Scholar
• Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin vs 5-fluorouracil, dox-orubicin, and mitomycin C vs 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-8. (C1/295)
   Google Scholar
• Cocconi G, Bella M, Zironi S, et al. Fluorouracil, doxoru-bicin, and mitomycin combination vs PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1994; 12: 2687-93. (C2/137)
   Google Scholar
• Cullinan SA, Moertel CG, Wieand HS, et al. Controlled evaluation of three drug combination regimens vs fluorou-racil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol. 1994; 12: 412-6. (C1/252)
   Google Scholar
• Loehrer PJ Sr, Harry D, Chlebowski RT. 5-fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma. Invest New Drugs 1994; 12: 57–63. (C3/ 165)
   Google Scholar
• Tsavaris NB, Tentas K, Kosmidis P, et al. 5-Fluorouracil, epirubicin, and mitomycin C vs 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial. Am J Clin Oncol 1996; 19: 517-21. (C2/88)
   Google Scholar
• Barone C, Corsi DC, Pozzo C, et al. Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies. Cancer 1998; 82: 1460-7. (C2/72)
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The Eu-ropean Organization for Research and Treatment of Cancer QLQ-C30: a Quality-of-Life instrument for use in the inter-national clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76. (01)
   Google Scholar
• de Haes J, van Knippenberg F, Neijt J. Measuring psycho-logical and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034-8. (01)
   PubMedGoogle Scholar